6 completed, 3 active not recruiting, 3 recruiting, 2 terminated. 16 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 6, Active not recruiting 3, Recruiting 3, Terminated 2, Not yet recruiting 1, Suspended 1 |
| Phase 2 | 7 | Completed 4, Active not recruiting 1, Recruiting 1, Terminated 1 |
Follow Chronic Graft Versus Host Disease: new trials by email Literature Review of Chronic Graft Versus Host Disease trials Research Report on Chronic Graft Versus Host Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male Participants Belumosudil - Chronic Graft Versus Host Disease | Phase 1 | Not yet recruiting | Sanofi | 58 | 2026-08-06 | 2026-07-24 |
| Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD Belumosudil - Chronic Graft Versus Host Disease | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 8 | 2026-02-09 | 2026-08-27 |
| Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD Fostamatinib, Ruxolitinib - Chronic Graft Versus Host Disease | Phase 1 | Recruiting | Stefanie Sarantopoulos, MD, PhD. | 30 | 2025-10-29 | 2026-01-22 |
| Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy Gecacitinib Hydrochloride Tablets - Chronic Graft Versus Host Disease | Phase 1 / Phase 2 | Recruiting | Yujun DONG | 24 | 2025-06-30 | 2025-06-10 |
| Upfront Ruxolitinib for Chronic Graft-vs-host Disease Ruxolitinib - Chronic Graft Versus Host Disease | Phase 1 | Terminated | Children's Hospital Medical Center, Cincinnati | 1 | 2025-02-19 | 2026-02-25 |
| Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation Biopsy, Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy - Chronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder | Phase 1 | Suspended | City of Hope Medical Center | 27 | 2024-02-19 | 2025-11-13 |
| A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease TQ05105 Tablet - Chronic Graft Versus Host Disease | Phase 1 / Phase 2 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 45 | 2021-06-25 | 2025-12-03 |
| Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease Leflunomide - Chronic Graft Versus Host Disease, Steroid Refractory Graft Versus Host Disease | Phase 1 | Active not recruiting | City of Hope Medical Center | 18 | 2020-09-14 | 2026-10-19 |
| Glasdegib for Chronic Graft-Versus-Host Disease Glasdegib - Chronic Graft Versus Host Disease, Fasciitis | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 15 | 2019-12-03 | 2024-10-29 |
| Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD) Ibrutinib - Chronic Graft Versus Host Disease | Phase 1 / Phase 2 | Completed | Pharmacyclics LLC. | 59 | 2018-11-19 | 2025-10-21 |
| Multiple Donor Treg DLI for Severe Refractory Chronic GVHD T reg DLI - Chronic Graft Versus Host Disease | Phase 1 / Phase 2 | Completed | Mario Arpinati | 18 | 2016-08-03 | 2023-02-02 |
| BMT Autologous MSCs for GvHD Autologous mesenchymal stromal cells (MSCs) - Graft Versus Host Disease, Acute Graft Versus Host Disease | Phase 1 | Completed | Emory University | 11 | 2015-01-01 | 2023-01-12 |
| Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD) Abatacept - Chronic Graft Versus Host Disease | Phase 1 / Phase 2 | Completed | Beth Israel Deaconess Medical Center | 56 | 2014-03-27 | 2026-05-29 |
| Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease Treg-enriched infusion, Interleukin-2 - Chronic Graft Versus Host Disease, Chronic GVHD | Phase 1 | Active not recruiting | Dana-Farber Cancer Institute | 25 | 2013-11-01 | 2026-02-05 |
| Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease Ofatumumab - Chronic Graft Versus Host Disease | Phase 1 / Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 44 | 2012-11-14 | 2022-10-06 |
| Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD nilotinib - Chronic Graft Versus Host Disease | Phase 1 | Completed | Gruppo Italiano Trapianto di Midollo Osseo | 22 | 2011-11-01 | 2023-03-10 |
Bronchiolitis Obliterans Syndrome (16) · Graft vs Host Disease (4) · Fasciitis (1) · Hematologic Diseases (1)
Bronchial Diseases (16) · Bronchiolitis (16) · Bronchiolitis Obliterans (16) · Bronchitis (16) · Immune System Diseases (16) · Lung Diseases (16) · Lung Diseases, Obstructive (16) · Organizing Pneumonia (16) · Respiratory Tract Diseases (16) · Graft vs Host Disease (12) · Hemic and Lymphatic Diseases (1) · Musculoskeletal Diseases (1)
belumosudil (2) · ruxolitinib (2) · Abatacept (1) · Biopsy (1) · Disulfides (1) · Immunoglobulins (1) · Immunotherapy, Adoptive (1) · Interleukin-2 (1) · Leflunomide (1) · Leukapheresis (1) · Magnetic Resonance Spectroscopy (1) · Phantoms, Imaging (1) · Specimen Handling (1) · Spinal Puncture (1) · X-Rays (1)
City of Hope Medical Center (2) · Beth Israel Deaconess Medical Center (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Children's Hospital Medical Center, Cincinnati (1) · Dana-Farber Cancer Institute (1) · Emory University (1) · Fred Hutchinson Cancer Center (1) · Gruppo Italiano Trapianto di Midollo Osseo (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · M.D. Anderson Cancer Center (1) · Mario Arpinati (1) · Pharmacyclics LLC. (1) · Sanofi (1) · Stefanie Sarantopoulos, MD, PhD. (1) · Yujun DONG (1)
United States (11) · Italy (3) · China (2) · Israel (2) · Australia (1) · Austria (1) · Canada (1) · France (1) · Germany (1) · Netherlands (1) · Russia (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Amandeep Salhotra (2) · Amin Alousi, MD (1) · Attilio Olivieri, MD (1) · Chenyu Lin, MD (1) · Gauri Sunkersett (1) · Jacalyn Rosenblatt, MD (1) · John Koreth, MBBS, DPhil (1) · Joseph Pidala, MD, MS (1) · Mario Arpinati (1) · Muna Qayed, MD (1) · Pooja Khandelwal, MD (1) · Stephanie Lee (1)
PMID 29549175, PMID 34649279, PMID 35475885, PMID 36189324, PMID 36862975, PMID 37698881, PMID 40009501
2017 (1), P30CA033572 (1), R01CA183559 (1)